Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab.
Loading...
Embargo End Date
ICR Authors
Authors
Schroeder, BA
Kohli, K
O'Malley, RB
Kim, TS
Jones, RL
Pierce, RH
Pollack, SM
Kohli, K
O'Malley, RB
Kim, TS
Jones, RL
Pierce, RH
Pollack, SM
Document Type
Journal Article
Date
2020-01-01
Date Accepted
2019-12-05
Abstract
Gastrointestinal stromal tumor (GIST) is a devastating disease, especially in the setting of metastasis. The natural progression of GIST has been significantly altered by the development of small molecule tyrosine kinase inhibitors (TKIs), including imatinib, sunitinib, and regorafenib, all of which are FDA approved. However, TKIs are not always well-tolerated, and the refractory disease continues to be a problem. For these reasons, alternative treatments are needed. In this report, we discuss a patient with metastatic wild-type (WT) GIST refractory to multiple TKIs, but with a durable clinical response to the anti-programmed cell death protein 1 (PD-1) antibody, nivolumab. This report suggests that continued research evaluating checkpoint inhibitors in GIST is warranted.
Citation
OncoImmunology, 2020, 9 (1), pp. 1710064 -
Source Title
OncoImmunology
Publisher
TAYLOR & FRANCIS INC
ISSN
2162-4011
eISSN
2162-402X
2162-402X
2162-402X